Jan 17 (Reuters) - The U.S. government has awarded Moderna MRNA.O $590 million to advance the late-stage development of its mRNA bird flu vaccine, as the country doubles down on efforts to tackle increasing infections in humans.
The award, funded by the Department of Health and Human Services, would be used to accelerate the development of mRNA-based pandemic influenza vaccines, a company spokesperson said on Friday.
The award was made through the Rapid Response Partnership Vehicle (RRPV) Consortium with funding from the U.S. Biomedical Advanced Research and Development Authority.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
((Mariam.ESunny@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。